Here you’ll find every edition of our newsletter. We share updates, milestones, and ways to stay engaged. Each issue is archived below for easy reference and transparency.
The geneTIGA project, funded by the EU’s Horizon Europe programme, is working to develop a groundbreaking cell therapy for IgA nephropathy (IgAN). The project aims to engineer T cells using advanced gene-editing techniques to selectively eliminate the harmful B cells driving IgAN, while sparing healthy cells. EKPF is a participant in this project, serving as a bridge between the consortium and patient organizations and ensuring that insights and feedback from IgAN Friends members contribute to the project’s direction.
17-20th September
IgAN Friends Joins IIGANN 2o25 in Prague
We’re excited to announce that IgAN Friends will be participating in the 18th International Symposium on IgA Nephropathy (IIGANN 2025), taking place from 17–20th September in Prague. This prestigious event brings together leading researchers, clinicians, and patient advocates to share the latest advancements in IgAN research, treatment, and care. As a patient-led organization, IgAN Friends is proud to contribute to the dialogue, ensuring that the patient voice remains central in shaping the future of IgAN.
4-7th June
IgAN Friends at the ERA Congress 2025
We were proud to attend the ERA Congress in Vienna, where we represented EKPF and the patient voice in three European projects: geneTIGA, KitNewCare, and PreventCKD. It was a great opportunity to raise awareness about IgAN Friends, a community for IgAN patients to share lived experiences and connect with fellow IgANers, while contributing to key discussions on patient-centered care and collaboration between patients and the medical community.
